anthracycline cardiotoxicity

Anthracycline Cardiotoxicity Exacerbated by Metabolic Stress in Pressure-Overloaded Hearts: Mechanistic Insights and Clinical Implications

By MedXY 09/21/2026

Left ventricular pressure overload induces metabolic vulnerability that heightens susceptibility to anthracycline cardiotoxicity, revealing a critical need for targeted preventive strategies in patients with hypertension or valvular disease undergoing chemotherapy.

Cardiology Hematology-Oncology news

Plasma Biomarkers CPVL and PIGR Predict Anthracycline-Induced Cardiotoxicity in Hematologic Cancer Patients

By MedXY 08/28/2026

Baseline plasma levels of CPVL and PIGR correlate with anthracycline-induced systolic dysfunction, offering potential early biomarkers for cardiotoxicity in hematologic malignancy patients undergoing chemotherapy.

Cardiology Hematology-Oncology news Oncology

Atorvastatin Preserves Aortic Elasticity During Anthracycline Chemotherapy: Secondary Analysis of STOP‑CA

By MedXY 11/25/2025

In a secondary analysis of the randomized STOP‑CA trial, atorvastatin 40 mg daily attenuated anthracycline‑associated increases in aortic stiffness measured by CMR pulse wave velocity, suggesting vascular protection and a potential strategy to reduce cardiotoxicity risk.